List of Excipients in Branded Drug ATENOLOL AND CHLORTHALIDONE

Generic Drugs Containing ATENOLOL AND CHLORTHALIDONE

Company	Ingredient	NDC	Excipient
Actavis Pharma Inc	atenolol and chlorthalidone	0591-5782	CELLULOSE, MICROCRYSTALLINE
Actavis Pharma Inc	atenolol and chlorthalidone	0591-5782	MAGNESIUM STEARATE
Actavis Pharma Inc	atenolol and chlorthalidone	0591-5782	POVIDONE

What are the Most Frequently-Used Excipients in ATENOLOL AND CHLORTHALIDONE?

# Of NDCs	Excipient
4	ANHYDROUS CITRIC ACID
14	CELLULOSE, MICROCRYSTALLINE
4	CROSCARMELLOSE SODIUM

Excipient Strategy and Commercial Opportunities for Atenolol and Chlorthalidone

Last updated: August 3, 2026

Atenolol/chlorthalidone is a mature fixed-dose antihypertensive combination with limited conventional patent protection and broad generic availability. Commercial value is concentrated in manufacturing efficiency, dose uniformity, dissolution control, packaging stability, supply reliability, and differentiated delivery formats rather than new-molecule exclusivity.

The strongest product opportunities are optimized immediate-release tablets, lower-cost global formulations, scored tablets for dose flexibility, and selected 505(b)(2) products with clinically meaningful administration advantages. The main technical challenge is balancing the highly water-soluble atenolol component with the poorly soluble, low-dose chlorthalidone component in a stable and bioequivalent tablet.

What is atenolol and chlorthalidone used for?

Atenolol/chlorthalidone is an oral fixed-dose combination for hypertension. Atenolol is a beta-1 selective adrenergic blocker. Chlorthalidone is a thiazide-like diuretic with a prolonged antihypertensive effect.

The original branded product, Tenoretic, was developed in two principal strengths:

Product strength	Atenolol	Chlorthalidone	Typical commercial role
Tenoretic 50/25	50 mg	25 mg	Lower beta-blocker dose
Tenoretic 100/25	100 mg	25 mg	Higher beta-blocker dose

The combination reduces blood pressure through complementary mechanisms. Chlorthalidone contributes substantial diuretic and electrolyte effects, while atenolol reduces heart rate and sympathetic activity. FDA labeling identifies the combination for hypertension management when the individual components at the selected doses are clinically appropriate. [1]

Atenolol/chlorthalidone is not generally positioned as a first-line fixed-dose combination in contemporary hypertension treatment guidelines because beta blockers have narrower routine roles than renin-angiotensin system inhibitors, calcium-channel blockers, and thiazide-type diuretics in many patients. Its commercial demand is therefore linked to established prescribing patterns, patient continuation, hospital formularies, and generic substitution.

What excipients are used in atenolol/chlorthalidone tablets?

Inactive ingredients vary by manufacturer, strength, market, and dosage form. Common excipient classes include fillers, binders, disintegrants, lubricants, glidants, surfactants, and coating systems.

Representative excipient categories are:

Excipient function	Candidate materials	Primary purpose
Diluent	Microcrystalline cellulose, lactose, dibasic calcium phosphate, mannitol	Tablet mass and compressibility
Binder	Povidone, copovidone, pregelatinized starch, hydroxypropyl cellulose	Granule and tablet strength
Disintegrant	Crospovidone, croscarmellose sodium, sodium starch glycolate	Tablet breakup
Lubricant	Magnesium stearate, sodium stearyl fumarate	Ejection and tooling protection
Glidant	Colloidal silicon dioxide, talc	Powder flow
Wetting agent	Sodium lauryl sulfate, poloxamer, polysorbate	Chlorthalidone wetting and dissolution
Film coating	Hypromellose, polyethylene glycol, titanium dioxide, iron oxides	Protection, identification, swallowability
Moisture-control packaging	Desiccant, high-barrier blister, aluminum-aluminum blister	Stability protection

The excipient composition of a proposed product should be compared against the reference listed drug and supported by pharmaceutical equivalence, dissolution, stability, and bioequivalence data. FDA DailyMed entries show that generic products can use materially different excipient systems while retaining the same active ingredients and strengths. [2]

How does the solubility profile affect excipient strategy?

The two active ingredients create different formulation problems.

Atenolol formulation considerations

Atenolol is relatively hydrophilic and presents less of a dissolution challenge than chlorthalidone. Key risks are:

• Segregation from the lower-dose chlorthalidone fraction.
• Content-uniformity failures during blending and compression.
• Sensitivity of disintegration and dissolution to excessive lubrication.
• Potential variability caused by granule density differences.

Atenolol’s high proportion of the tablet can dominate powder flow and compression behavior. Direct compression may be feasible if the selected grades of microcrystalline cellulose, mannitol, or dibasic calcium phosphate provide adequate flow and compactability.

Chlorthalidone formulation considerations

Chlorthalidone is present at a lower dose but generally creates the more difficult dissolution problem. A formulation may require:

• Fine particle-size control.
• Wet granulation or engineered dry granulation.
• A wetting agent or surfactant.
• Controlled hydrophobic lubrication.
• Particle-size and polymorph monitoring.
• Robust content-uniformity controls.

A surfactant can improve wetting, but excessive surfactant may affect tablet hardness, disintegration, gastrointestinal tolerability, and dissolution reproducibility. The formulation target should be rapid and consistent release without creating a large formulation difference from the reference product.

Combination-product risk

The most important development risk is not the individual active ingredients. It is the interaction between the two powders and the excipient system. A low-dose chlorthalidone blend can segregate during hopper transfer, compression, or tablet dedusting.

Risk controls include:

1. Matching particle-size distributions where practical.
2. Using ordered mixing or carrier-based blending.
3. Limiting transfer distances after final blending.
4. Validating blend uniformity at commercial batch scale.
5. Setting in-process controls for tablet weight, hardness, friability, and assay.
6. Testing dissolution by strength and manufacturing site.

What formulation strategies are commercially attractive?

Immediate-release film-coated tablets

Immediate-release tablets remain the lowest-risk commercial format. The primary opportunity is a robust, low-cost formulation with:

• Consistent dissolution of chlorthalidone.
• Strong content uniformity.
• Low tablet weight.
• Scoring where permitted.
• Simple film coating.
• Broad excipient sourcing.

A conventional immediate-release tablet is usually preferable for an ANDA because it minimizes regulatory complexity and avoids unnecessary clinical differentiation.

Scored tablets

Scoring can create a practical value proposition for patients who require dose adjustment or have difficulty swallowing whole tablets. Atenolol/chlorthalidone tablets should not be marketed as functionally divisible unless the score is validated for subdivision uniformity and the labeling supports that use.

A scored 50/25 tablet could create flexibility around beta-blocker dosing, but the commercial value depends on whether the divided portions deliver acceptable dose accuracy for both active ingredients. Because the fixed ratio may not suit all patients, scoring alone does not eliminate the clinical limitation of a fixed-dose combination.

Smaller tablets

Tablet size is a meaningful opportunity because the product contains a relatively high atenolol load plus excipients needed to disperse chlorthalidone. High-density direct-compression systems, roller compaction, or optimized granulation can reduce tablet volume.

A smaller tablet may improve adherence and swallowability, especially for older patients taking multiple medicines. The formulation must retain acceptable hardness and rapid disintegration.

Orally disintegrating tablets

An orally disintegrating tablet could provide differentiation for patients with dysphagia or limited access to water. The commercial case is weaker than for standard tablets because:

• Atenolol and chlorthalidone have a pronounced pharmacologic effect and are not ideal candidates for casual administration.
• Chlorthalidone’s low solubility complicates fast release.
• Taste masking may be needed.
• A 25 mg chlorthalidone dose may create taste and mouthfeel challenges.
• FDA may require product-specific bioequivalence evidence beyond a conventional ANDA pathway depending on the design.

An ODT is more suitable for a 505(b)(2) strategy if the sponsor can demonstrate a clinically useful administration advantage.

Modified-release products

Modified release is technically possible but commercially difficult. Chlorthalidone already has a long duration of action, and atenolol does not necessarily create a strong clinical need for extended release in this combination. A modified-release product would face formulation, pharmacokinetic, safety, and labeling burdens without an obvious market gap.

Liquid or multiparticulate products

A liquid product could address pediatric, geriatric, or enteral-tube administration, but chlorthalidone’s solubility and physical stability would require careful suspension design. Important development issues include:

• Sedimentation and redispersibility.
• Dose uniformity after storage.
• Preservative compatibility.
• Container closure performance.
• Palatability.
• Tube compatibility.
• Chemical and microbiological stability.

A suspension may have value in institutional and specialty channels, but the addressable market is smaller than for standard tablets.

What manufacturing and excipient barriers exist?

The main manufacturing barriers are process-control barriers rather than active-ingredient scarcity.

Content uniformity

Chlorthalidone’s lower dose increases the risk of nonuniform distribution. The sponsor should establish a validated sampling plan covering:

• Precompression blend.
• Tablet cores.
• Start, middle, and end of compression.
• Multiple compression stations where applicable.
• Finished-product assay by active ingredient.

Near-infrared or other process analytical technology can support real-time monitoring, but the economic case depends on batch size and manufacturing complexity.

Dissolution

The dissolution method must distinguish poor wetting from poor disintegration and must detect changes in particle size, granulation, lubricant level, and surfactant concentration. A robust formulation should demonstrate a stable dissolution profile across:

• Pilot and commercial batches.
• Normal and accelerated stability.
• Different API lots.
• Expected manufacturing-scale variation.

Moisture and packaging

Moisture can affect tablet hardness, disintegration, coating performance, and API stability. The appropriate packaging decision depends on the selected formulation and stability data. Bottles with desiccants may minimize cost, while high-barrier blisters may improve dose protection and adherence.

Packaging differentiation can create commercial value in humid markets and institutional settings. It also affects serialization, dispensing efficiency, and supply-chain cost.

API sourcing

Atenolol is generally available from multiple suppliers. Chlorthalidone may have a narrower qualified-supplier base, depending on jurisdiction and required regulatory documentation. Dual sourcing can reduce supply risk but may require comparability work if particle size, polymorphic form, impurity profile, or bulk density differs.

What regulatory pathway applies to atenolol/chlorthalidone?

A conventional generic tablet would ordinarily pursue an ANDA under section 505(j) of the Federal Food, Drug, and Cosmetic Act. The reference product is Tenoretic or an FDA-designated reference listed drug, subject to the applicable FDA product-specific guidance and Orange Book requirements. [3,4]

A differentiated dosage form, new route, new strength, or clinically meaningful administration change may require a 505(b)(2) application. The pathway depends on the extent to which the sponsor relies on FDA findings for the listed drugs and the degree of new investigation required.

Key regulatory workstreams include:

Workstream	Commercial relevance
Pharmaceutical equivalence	Establishes same active ingredients, strength, dosage form, and route
Bioequivalence	Supports substitutability or approval of the proposed product
Dissolution	Identifies release and manufacturing sensitivity
Stability	Determines shelf life and packaging requirements
Inactive-ingredient review	Addresses safety and route-specific acceptability
Labeling	Must reflect the approved combination product and warnings
Manufacturing validation	Controls blend uniformity and scale-up risk

FDA labeling warns about bradycardia, hypotension, electrolyte disturbances, renal impairment, and masking of hypoglycemia, among other risks. [1] These safety issues limit aggressive consumer positioning and make formulation changes clinically relevant if they alter exposure or dose flexibility.

What patents protect atenolol/chlorthalidone?

The original composition-of-matter and product patent estate is historical and does not provide a meaningful current barrier to conventional generic entry. The commercial product has been available for decades, and atenolol/chlorthalidone is sold by multiple generic manufacturers.

The Orange Book remains the authoritative source for current patent and regulatory-exclusivity listings for approved drug products. [4] For a live launch decision, the sponsor must assess the current Orange Book entry, applicable pediatric exclusivity, FDA exclusivity codes, and any product-specific litigation record.

Potential residual IP categories include:

• Formulation patents covering a specific excipient system.
• Manufacturing patents covering granulation or particle engineering.
• Scored-tablet or dose-delivery patents.
• ODT or liquid dosage-form patents.
• Method-of-use patents directed to a defined patient population.
• Packaging or stability patents.
• Foreign-country formulation rights.

These categories are unlikely to block a conventional immediate-release generic unless a live, enforceable patent is listed or separately asserted against the proposed product.

When does atenolol/chlorthalidone lose exclusivity?

The original branded combination lost practical market exclusivity long ago. Generic entry is established in the United States and other major markets. Current competition is therefore based on price, supply continuity, manufacturing quality, wholesaler access, and formulary positioning.

There is no meaningful biosimilar pathway because atenolol and chlorthalidone are synthetic small molecules, not biologics. Biosimilar risk is not relevant. The competitive threat comes from:

• Other atenolol/chlorthalidone generics.
• Atenolol monotherapy.
• Chlorthalidone monotherapy.
• Hydrochlorothiazide combinations.
• Beta blocker/calcium-channel blocker combinations.
• Fixed-dose combinations containing an ACE inhibitor, ARB, or calcium-channel blocker.

How many patents cover atenolol/chlorthalidone?

The number of commercially relevant patents is likely low for the legacy immediate-release combination. Patent-count analysis should separate:

1. Expired original patents.
2. Current Orange Book-listed patents.
3. Unlisted formulation or process patents.
4. Foreign patents.
5. Patents covering competing dosage forms rather than the standard tablet.

A simple patent count can misstate risk. One active formulation patent may be more important than numerous expired patents, while an unlisted process patent may create manufacturing exposure without preventing ANDA approval.

For a standard generic tablet, the practical IP strategy is usually:

• Conduct Orange Book review.
• Search formulation and process patents in the relevant jurisdictions.
• Compare the proposed excipient composition with known products.
• Document independent formulation development.
• Evaluate Paragraph IV exposure if a listed patent is identified.
• Preserve design-around evidence for any asserted patent.

Which companies are challenging the atenolol/chlorthalidone market?

The product is already a multi-source generic category. Competition is typically distributed among established generic manufacturers, contract manufacturers, and regional suppliers rather than concentrated in a single innovator challenger.

Competitive differentiation is most likely through:

• Lower cost of goods.
• Reliable supply during shortages.
• Multiple package sizes.
• Hospital and government contracts.
• Authorized-generic or private-label arrangements.
• Dual-source API qualification.
• Better blister packaging.
• Regional regulatory registrations.

The largest threat to a new entrant is not a patent lawsuit. It is price erosion and difficulty securing durable channel access.

What licensing deals and commercial opportunities exist?

Licensing opportunities are more likely to involve manufacturing rights, regional registrations, private-label supply, or portfolio bundling than high-value patent licensing.

Potential commercial structures include:

Opportunity	Value proposition
Regional licensing	Access to markets where few suppliers are registered
Contract manufacturing	Uses existing tablet and coating capacity
Private-label supply	Adds product breadth for distributors
Hospital tenders	Rewards low price and supply reliability
Government procurement	Favors validated, scalable production
Portfolio bundling	Combines the product with other cardiovascular generics
505(b)(2) partnership	Shares development cost for ODT, liquid, or adherence-focused formats

A standard ANDA product is most attractive for a manufacturer with existing cardiovascular infrastructure and a low-cost supply chain. A differentiated dosage form requires a stronger commercial case and a clearer reimbursement or adherence benefit.

What is the revenue exposure for atenolol/chlorthalidone?

Revenue potential is moderate to low on a unit basis and depends heavily on scale. The category is mature, generic, and exposed to reimbursement compression. Margin can be improved through:

• High-volume production.
• Low tablet weight.
• Limited SKU complexity.
• Efficient packaging.
• Low reject rates.
• Dual-source API procurement.
• Automated inspection and release testing.

The 50/25 mg and 100/25 mg strengths should be evaluated separately. Demand may be uneven by market, with one strength accounting for most prescriptions. Launching both strengths improves formulary coverage but increases validation, packaging, and inventory requirements.

How strong is the patent estate for atenolol/chlorthalidone?

The patent estate is weak for a conventional immediate-release generic and potentially stronger only for new delivery systems or narrow formulation claims.

Product concept	Patent strength	Regulatory complexity	Commercial attractiveness
Conventional immediate-release tablet	Low	Low	Moderate at scale
Scored tablet	Low to moderate	Moderate	Moderate
Smaller high-density tablet	Moderate if novel	Moderate	Moderate
ODT	Moderate	High	Selective
Oral suspension	Moderate	High	Niche
Modified release	Moderate	High	Low to moderate
Novel particle-engineered formulation	Moderate to high	High	Depends on clinical benefit

The most defensible IP opportunity would require a measurable technical advantage, such as improved chlorthalidone dissolution, verified dose uniformity, superior stability, or a clinically meaningful administration benefit.

What generic launch risks exist?

Generic launch risk is primarily commercial and operational.

Principal risks

• Price erosion after additional entrants.
• Failure to achieve chlorthalidone content uniformity.
• Dissolution failure after scale-up.
• Inconsistent API particle size.
• Packaging-related stability loss.
• Limited demand for one of the two strengths.
• Channel concentration among a few wholesalers.
• Regulatory delay caused by facility or data deficiencies.
• Product recalls caused by manufacturing deviations.
• Competition from single-ingredient alternatives.

A launch plan should prioritize a formulation that is easy to manufacture repeatedly rather than one that maximizes excipient novelty.

What geographic markets offer opportunity?

The strongest geographic opportunities are markets with:

• Established use of atenolol.
• Continued use of thiazide-type diuretics.
• Limited local generic competition.
• Public-sector procurement.
• High demand for low-cost antihypertensives.
• Local registration pathways recognizing US, EU, or other reference approvals.

Regulatory requirements differ by jurisdiction. A formulation accepted in the United States may require separate bioequivalence, stability, impurity, excipient, or packaging documentation elsewhere. The product should be assessed against local strength conventions, tablet scoring requirements, labeling rules, and prescription status.

Key Takeaways

• Atenolol/chlorthalidone is a mature generic fixed-dose combination with little practical legacy patent protection.
• The principal formulation problem is low-dose chlorthalidone uniformity and dissolution within a tablet dominated by atenolol.
• Direct compression or optimized granulation can support a low-cost immediate-release product.
• Surfactants, particle-size control, and lubrication management are important to chlorthalidone dissolution.
• Scored tablets and smaller tablets offer practical differentiation without the full burden of a novel delivery system.
• ODT, liquid, and modified-release products may qualify for 505(b)(2) development but require a clear clinical or commercial rationale.
• Biosimilar competition is irrelevant because the product contains synthetic small molecules.
• Commercial success depends more on cost, supply reliability, packaging, and channel access than on patent exclusivity.
• The most attractive launch profile is a two-strength, immediate-release product with strong blend uniformity, scalable manufacturing, and reliable stability data.

FAQs

Can atenolol and chlorthalidone be combined in one tablet with different release rates?

Yes, but a release-rate difference increases development and regulatory complexity. A conventional immediate-release tablet is generally the lowest-risk approach.

Which excipient is most important for chlorthalidone dissolution?

No single excipient is universally optimal. Wetting agents, particle-size control, disintegrants, and lubricant concentration must be evaluated together because their effects are formulation-dependent.

Is atenolol/chlorthalidone suitable for an authorized generic?

Yes. An authorized generic or private-label arrangement may be commercially viable where the sponsor has access to approved manufacturing capacity and distribution channels.

Can a new atenolol/chlorthalidone formulation receive new patent protection?

Potentially, but protection would need to focus on a genuinely novel and nonobvious formulation, process, delivery system, or stability solution. The active ingredients themselves do not provide a new patent barrier.

Is chlorthalidone preferable to hydrochlorothiazide in a fixed-dose product?

Chlorthalidone has a longer duration of action and distinct clinical-use characteristics. Commercial preference depends on physician adoption, labeling, reimbursement, safety positioning, and the competitive strength of hydrochlorothiazide combinations.

References

1. U.S. Food and Drug Administration. (2023). Tenoretic- atenolol and chlorthalidone tablet, film coated: Prescribing information. DailyMed. https://dailymed.nlm.nih.gov/

2. National Library of Medicine. (2024). Atenolol and chlorthalidone tablet products. DailyMed. https://dailymed.nlm.nih.gov/

3. U.S. Food and Drug Administration. (2024). Abbreviated new drug application (ANDA) process. https://www.fda.gov/drugs/types-applications/abbreviated-new-drug-application-anda

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

5. U.S. Food and Drug Administration. (2024). Applications covered by section 505(b)(2). https://www.fda.gov/drugs/types-applications/abbreviated-new-drug-application-anda/application-types-and-submissions-505b2-vesm fda?